AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20437564 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-interval T2-weighted subtraction (T2w-Sub) imaging
Number of subjects: 120
Study 20437564 — intervention group
Group type: COMPARATOR
Intervention: Monthly gadolinium-enhanced T1-weighted (Gd-T1w) imaging
Number of subjects: 120
Study 18672190 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 0
Study 18672190 — intervention group
Group type: COMPARATOR
Intervention: Glyburide
Number of subjects: 0
Study 16165718 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ferrous fumarate (Neo‐fer) 120 mg orally once daily
Number of subjects: 19
Study 16165718 — intervention group
Group type: COMPARATOR
Intervention: Intravenous iron sucrose (Venofer) 200 mg intravenously 3 times during a period of 14 days
Number of subjects: 19
Study 12835216 — intervention group
Group type: EXPERIMENTAL
Intervention: FilterWire-Ex (FW)
Number of subjects: 53
Study 10809863 — intervention group
Group type: EXPERIMENTAL
Intervention: Odorants with a sedative effect
Number of subjects: 0
Study 10809863 — intervention group
Group type: COMPARATOR
Intervention: Other odorants
Number of subjects: 0
Study 8665383 — intervention group
Group type: EXPERIMENTAL
Intervention: Praziquantel 30 mg/kg
Number of subjects: 301
Study 2005563 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of lidocaine, epinephrine, hyaluronidase with bupivacaine
Number of subjects: 117
Study 2005563 — intervention group
Group type: COMPARATOR
Intervention: Any other combinations of lidocaine, epinephrine, and hyaluronidase with bupivacaine
Number of subjects: 117
Study 6519165 — intervention group
Group type: EXPERIMENTAL
Intervention: Lasix (40 mg)
Number of subjects: 8
Study 6519165 — intervention group
Group type: EXPERIMENTAL
Intervention: Furix (40 mg)
Number of subjects: 8
Study 6519165 — intervention group
Group type: COMPARATOR
Intervention: Intravenous furosemide
Number of subjects: 8
Study 6519165 — intervention group
Group type: EXPERIMENTAL
Intervention: Lasix and Furix
Number of subjects: 8
Study 31118148 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory event monitoring (AEM) for 30 days post-TAVR
Number of subjects: 150
Study 31118148 — intervention group
Group type: EXPERIMENTAL
Intervention: Right bundle branch block (RBBB) as a risk factor
Number of subjects: 150
Study 31118148 — intervention group
Group type: COMPARATOR
Intervention: Patients without incident high-grade atrioventricular block (H-AVB)
Number of subjects: 150
Study 29458928 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (28,000 IU weekly for 8 weeks)
Number of subjects: 125
Study 29458928 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study 27736842 — intervention group
Group type: EXPERIMENTAL
Intervention: Panitumumab plus best supportive care (BSC)
Number of subjects: 377
Study 27736842 — intervention group
Group type: COMPARATOR
Intervention: Best supportive care (BSC)
Number of subjects: 377
Study 27736842 — intervention group
Group type: EXPERIMENTAL
Intervention: Panitumumab plus best supportive care (BSC) in wild-type RAS mCRC
Number of subjects: 377
Study 27736842 — intervention group
Group type: COMPARATOR
Intervention: Best supportive care (BSC) in wild-type RAS mCRC
Number of subjects: 377
Study 27736842 — intervention group
Group type: EXPERIMENTAL
Intervention: Panitumumab in patients with RAS mutations
Number of subjects: 377
Study 24881917 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate 1 g/m(2) over 24 hours with intrathecal injection (MTX1 arm)
Number of subjects: 44
Study 24881917 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate 3 g/m(2) over 3 hours without intrathecal injection (MTX3 arm)
Number of subjects: 44
Study 24881917 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment in Japan (both MTX1 and MTX3 arms)
Number of subjects: 44
Study 24881917 — intervention group
Group type: COMPARATOR
Intervention: Overall treatment in international study (both MTX1 and MTX3 arms)
Number of subjects: 44
Study 22552038 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 μg vitamin D3 daily for 10 weeks
Number of subjects: 56
Study 22552038 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 μg 25-hydroxyvitamin D3 daily for 10 weeks
Number of subjects: 56
Study 22552038 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 μg 25-hydroxyvitamin D3 daily for 10 weeks
Number of subjects: 56
Study 22552038 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 20095068 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 101
Study 20095068 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone
Number of subjects: 101
Study 20095068 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study 17388752 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyproheptadine hydrochloride (CH) 2 mg QID for 1 week followed by 4 mg QID for 11 weeks
Number of subjects: 16
Study 17388752 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 15576390 — intervention group
Group type: EXPERIMENTAL
Intervention: rLH supplementation (150 IU) in addition to rFSH (225 IU starting dose)
Number of subjects: 260
Study 15576390 — intervention group
Group type: COMPARATOR
Intervention: rFSH step-up protocol (increased by 150 IU)
Number of subjects: 260
Study 15576390 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal responders with rFSH monotherapy)
Number of subjects: 260
Study 12213688 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine
Number of subjects: 255
Study 12213688 — intervention group
Group type: COMPARATOR
Intervention: Paroxetine
Number of subjects: 255
Study 9466083 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole 1 percent cream applied once daily
Number of subjects: 0
Study 9466083 — intervention group
Group type: COMPARATOR
Intervention: Vehicle cream
Number of subjects: 0
Study 8595079 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical anaesthesia with liposomal gel formulation containing 2% tetracaine
Number of subjects: 0
Study 8595079 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro drug liberation
Number of subjects: 0
Study 8595079 — intervention group
Group type: EXPERIMENTAL
Intervention: In vivo penetration rate of tetracaine
Number of subjects: 0
Study 1974941 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylfolate, 15 mg daily for 6 months in addition to standard psychotropic treatment
Number of subjects: 123
Study 1974941 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 123
Study 141633 — intervention group
Group type: EXPERIMENTAL
Intervention: Falope-Ring banding
Number of subjects: 150
Study 141633 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% Xylocaine applied to the tubes during Falope-Ring banding
Number of subjects: 150
Study 141633 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic tubal fulguration
Number of subjects: 150
Study 30617490 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadobutrol
Number of subjects: 40
Study 30617490 — intervention group
Group type: COMPARATOR
Intervention: Gadoterate meglumine
Number of subjects: 40
Study 30003324 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen gel phonophoresis
Number of subjects: 61
Study 30003324 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen cream phonophoresis
Number of subjects: 61
Study 26582047 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (0.5 mg/kg at induction, followed by 0.25 mg/kg/h continuous infusion for 30 min)
Number of subjects: 120
Study 26582047 — intervention group
Group type: COMPARATOR
Intervention: Control (0.9% saline, 0.05 ml/kg at induction, followed by 0.025 ml/kg/h continuous infusion for 30 min)
Number of subjects: 120
Study 25323181 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactated Ringer's (LR) solution
Number of subjects: 78
Study 25323181 — intervention group
Group type: COMPARATOR
Intervention: 4.3% dextrose in 0.18% saline (DS)
Number of subjects: 78
Study 22997792 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupotomy treatment once a week for 3 weeks.
Number of subjects: 180
Study 22997792 — intervention group
Group type: COMPARATOR
Intervention: Electroacupuncture treatment 3 times a week for 3 weeks.
Number of subjects: 180
Study 20332722 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional neuro-rehabilitation protocol (therapeutic exercise and occupational therapy) plus 60 minutes of mental practice training for 3 weeks
Number of subjects: 36
Study 20332722 — intervention group
Group type: COMPARATOR
Intervention: Conventional neuro-rehabilitation protocol (therapeutic exercise and occupational therapy) for 3 weeks
Number of subjects: 36
Study 20332722 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation program plus mental practice training for 3 weeks
Number of subjects: 36
Study 20332722 — intervention group
Group type: COMPARATOR
Intervention: Conventional neuro-rehabilitation program for 3 weeks
Number of subjects: 36
Study 17341751 — intervention group
Group type: EXPERIMENTAL
Intervention: Short form data entry strategy
Number of subjects: 100
Study 17341751 — intervention group
Group type: COMPARATOR
Intervention: Long form data entry strategy
Number of subjects: 100
Study 16184722 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone
Number of subjects: 40
Study 16184722 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac potassium
Number of subjects: 40
Study 12452936 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole 20 mg
Number of subjects: 221
Study 12452936 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole 40 mg
Number of subjects: 221
Study 12452936 — intervention group
Group type: COMPARATOR
Intervention: Nizatidine 150 mg
Number of subjects: 221
Study 10077172 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with recombinant interferon-alpha2b (rIFN-alpha2b) and zidovudine (ZDV)
Number of subjects: 256
Study 10077172 — intervention group
Group type: COMPARATOR
Intervention: Zidovudine (ZDV) alone
Number of subjects: 256
Study 7745037 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid in seminal plasma
Number of subjects: 46
Study 7745037 — intervention group
Group type: EXPERIMENTAL
Intervention: Urate concentrations in seminal plasma
Number of subjects: 46
Study 7745037 — intervention group
Group type: EXPERIMENTAL
Intervention: Luminol-chemiluminescence (CL) in washed semen
Number of subjects: 46
Study 7745037 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of ascorbic acid with CL signals
Number of subjects: 46
Study 7745037 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of ascorbic acid with sperm morphology
Number of subjects: 46
Study 2285619 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 10
Study 2285619 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 6938242 — intervention group
Group type: EXPERIMENTAL
Intervention: New drug combination (cincain chloride, tri‐iodomethane, tranexamic acid, propyl‐hydroxy‐benzoic acid in Gelfoam)
Number of subjects: 15
Study 6938242 — intervention group
Group type: COMPARATOR
Intervention: Control group (sockets allowed to heal spontaneously)
Number of subjects: 15
Study 30932783 — intervention group
Group type: EXPERIMENTAL
Intervention: RNI+ (patients with rapid neurological improvement)
Number of subjects: 91
Study 28606102 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 26189808 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment (rotator cuff repair)
Number of subjects: 56
Study 26189808 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 56
Study 26189808 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment (rotator cuff repair) without retear
Number of subjects: 56
Study 23484041 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive iPad presentation
Number of subjects: 90
Study 23484041 — intervention group
Group type: COMPARATOR
Intervention: Paper consent
Number of subjects: 90
Study 21057805 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Number of subjects: 1019
Study 21057805 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy
Number of subjects: 1019
Study 21057805 — intervention group
Group type: COMPARATOR
Intervention: Ranibizumab-based therapy
Number of subjects: 1019
Study 21057805 — intervention group
Group type: COMPARATOR
Intervention: Low vision rehabilitation
Number of subjects: 1019
Study 21057805 — intervention group
Group type: COMPARATOR
Intervention: Visual acuity
Number of subjects: 1019
Study 21057805 — intervention group
Group type: COMPARATOR
Intervention: Choroidal neovascularisation
Number of subjects: 1019
Study 19054783 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg/day soy isoflavones
Number of subjects: 50
Study 19054783 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 17309452 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelaic acid applied once a day
Number of subjects: 65
Study 17309452 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzoyl peroxide
Number of subjects: 65
Study 17309452 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapalene
Number of subjects: 65
Study 15539961 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (10 mg q x d)
Number of subjects: 45
Study 10235419 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen 25 mg
Number of subjects: 108
Study 10235419 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen 50 mg
Number of subjects: 108
Study 10235419 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyrone 500 mg
Number of subjects: 108
Study 10235419 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study 8966143 — intervention group
Group type: EXPERIMENTAL
Intervention: Benazepril (10 mg once daily)
Number of subjects: 31
Study 8966143 — intervention group
Group type: COMPARATOR
Intervention: Captopril (50 mg once daily)
Number of subjects: 31
Study 1758250 — intervention group
Group type: EXPERIMENTAL
Intervention: IG/IH nerve block (0.25% bupivacaine, 1 mg/kg)
Number of subjects: 75
Study 1758250 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous fentanyl (1 microgram/kg)
Number of subjects: 75
Study 1758250 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia (Control)
Number of subjects: 75
Study 7117428 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral salbutamol
Number of subjects: 10
Study 7117428 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined oral and inhalation salbutamol
Number of subjects: 10
Study 7117428 — intervention group
Group type: COMPARATOR
Intervention: Combined therapy (oral and inhalation)
Number of subjects: 10
Study 30659063 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT) plus asthma education
Number of subjects: 168
Study 30659063 — intervention group
Group type: COMPARATOR
Intervention: Asthma education talk plus 3 telephone follow‐ups (control group)
Number of subjects: 168
Study 28347296 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A questionnaire pack (4 pages: demographic and EQ-5D-3L questionnaires)
Number of subjects: 18190
Study 28347296 — intervention group
Group type: COMPARATOR
Intervention: Group B questionnaire pack (8 pages: HADS and PCL-C questionnaires included)
Number of subjects: 18190
Study 28347296 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (EQ-5D-3L mobility domain)
Number of subjects: 18190
Study 28347296 — intervention group
Group type: COMPARATOR
Intervention: Group B (EQ-5D-3L mobility domain)
Number of subjects: 18190
Study 28347296 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (anxiety/depression domain)
Number of subjects: 18190
Study 28347296 — intervention group
Group type: COMPARATOR
Intervention: Group B (anxiety/depression domain)
Number of subjects: 18190
Study 25181946 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg prednisolone per day, tapered to 5 mg over 8 weeks
Number of subjects: 450
Study 25181946 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg prednisolone per day, tapered to 5 mg over 8 weeks
Number of subjects: 450
Study 25181946 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 450
Study 25181946 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg prednisolone per day
Number of subjects: 450
Study 25181946 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg prednisolone per day
Number of subjects: 450
Study 22909076 — intervention group
Group type: EXPERIMENTAL
Intervention: self‐administered relaxation acupressure
Number of subjects: 375
Study 22909076 — intervention group
Group type: EXPERIMENTAL
Intervention: self‐administered stimulating acupressure
Number of subjects: 375
Study 22909076 — intervention group
Group type: COMPARATOR
Intervention: standard of care
Number of subjects: 375
Study 20631491 — intervention group
Group type: EXPERIMENTAL
Intervention: SALB (0.06 microg/kg/min iv from 0 to 60 min)
Number of subjects: 6
Study 20631491 — intervention group
Group type: EXPERIMENTAL
Intervention: SALB (0.06 microg/kg/min iv from 0 to 60 min) + AG (1.0 microg/kg/min iv from ‐60 to 60 min)
Number of subjects: 6
Study 20631491 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline
Number of subjects: 6
Study 18946667 — intervention group
Group type: EXPERIMENTAL
Intervention: Lemon juice (60 mEq/day, approximately 85 cc/day)
Number of subjects: 30
Study 18946667 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium citrate (60 mEq/day)
Number of subjects: 30
Study 18946667 — intervention group
Group type: COMPARATOR
Intervention: Dietary recommendations
Number of subjects: 30
Study 16211207 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 20
Study 16211207 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol tartrate
Number of subjects: 20
Study 11802748 — intervention group
Group type: COMPARATOR
Intervention: 5-day treatment with 3 antibiotics (amoxicillin 1 g bid, clarithromycin 250 mg bid, metronidazole 400 mg bid) and lansoprazole 30 mg bid (L5)
Number of subjects: 243
Study 11802748 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-day antibiotic-lansoprazole combination (L3) with a 2-day pretreatment with lansoprazole
Number of subjects: 243
Study 11802748 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-day treatment with 3 antibiotics and ranitidine hydrochloride 300 mg bid (R5)
Number of subjects: 243
Study 10621929 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal remedy (Radix echinaceae, Radix baptisiae, Herba thujae), 3 tablets t.i.d. for 7 to 9 days
Number of subjects: 263
Study 10621929 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 263
Study 8565486 — intervention group
Group type: EXPERIMENTAL
Intervention: Empty patch
Number of subjects: 8
Study 8565486 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium lauryl sulfate (SLS) and hydrochloric acid (HCl)
Number of subjects: 8
Study 8565486 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonanoic acid (NON)
Number of subjects: 8
Study 8565486 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine (IMI) 2.5%
Number of subjects: 8
Study 1955502 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethinyl estradiol (EE; 100 ng/kg.day) after 1 week
Number of subjects: 9
Study 1955502 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethinyl estradiol (EE; 100 ng/kg.day) after 5 weeks
Number of subjects: 9
Study 1955502 — intervention group
Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 9
Study 6874890 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg testosterone enanthate
Number of subjects: 6
Study 6874890 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg testosterone enanthate
Number of subjects: 6
Study 6874890 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 6874890 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone treatment
Number of subjects: 6
Study 31072850 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month supervised multimodal exercise programme combined with omega-3 fatty acid, vitamin D and protein supplementation
Number of subjects: 148
Study 31072850 — intervention group
Group type: COMPARATOR
Intervention: Stretching/flexibility exercise programme combined with placebo supplements
Number of subjects: 148
Study 29863974 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperfractionated cyclophosphamide (hyper‐C)
Number of subjects: 787
Study 29863974 — intervention group
Group type: COMPARATOR
Intervention: Standard dose of cyclophosphamide
Number of subjects: 787
Study 28004008 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediabetes
Number of subjects: 593
Study 28004008 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes
Number of subjects: 593
Study 28004008 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase 1 prediabetics
Number of subjects: 593
Study 28004008 — intervention group
Group type: EXPERIMENTAL
Intervention: Age, family history of diabetes, and gender
Number of subjects: 593
Study 28004008 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 593
Study 28004008 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 diabetes
Number of subjects: 593
Study 24770501 — intervention group
Group type: EXPERIMENTAL
Intervention: Three sessions of 1540nm fractional Erbium laser (50 mJ/mB, 15ms, 2 passes)
Number of subjects: 18
Study 24770501 — intervention group
Group type: COMPARATOR
Intervention: One session of 2940nm Erbium laser (5mJ/mB, 0.25ms, 2 passes)
Number of subjects: 18
Study 24770501 — intervention group
Group type: COMPARATOR
Intervention: One session of 2940nm Erbium laser
Number of subjects: 18
Study 23281754 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium hydrosulfide (NaHS, 10 µmol/kg body weight/day)
Number of subjects: 100
Study 23281754 — intervention group
Group type: COMPARATOR
Intervention: D, L-propargylglycerine (CSE inhibitor)
Number of subjects: 100
Study 23281754 — intervention group
Group type: COMPARATOR
Intervention: Normoxic conditions
Number of subjects: 100
Study 20384610 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic mixture (VSL#3)
Number of subjects: 20
Study 20384610 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 17993874 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium sulfate group (8 patients)
Number of subjects: 13
Study 17993874 — intervention group
Group type: COMPARATOR
Intervention: Control group (5 patients)
Number of subjects: 13
Study 17325091 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling-based weaning intervention
Number of subjects: 48
Study 17325091 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 48